Skip Navigation



JAC Advance Access published online on April 14, 2006

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl142
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/6/1077    most recent
dkl142v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hasegawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasegawa, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received December 9, 2005
Revised March 13, 2006
Accepted March 20, 2006

Original article

High prevalence of type b {beta}-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced

Keiko Hasegawa 1, Reiko Kobayashi 1, Emi Takada 1, Akiko Ono 1, Naoko Chiba 1, Miyuki Morozumi 1, Satoshi Iwata 2, Keisuke Sunakawa 3, Kimiko Ubukata 1 *, and on behalf of the Working Group of the Nationwide Surveillance for Bacterial Meningitis

1 Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, Japan
2 National Hospital Organization Tokyo Medical Center, Tokyo, Japan
3 Department of Infectious Disease, Kitasato University School of Medicine, Kanagawa, Japan

* To whom correspondence should be addressed.
Kimiko Ubukata, E-mail: ubukatak{at}lisci.kitasato-u.ac.jp


   Abstract

Objectives: To study yearly changes in resistance and to identify ftsI mutations in {beta}-lactamase-non-producing ampicillin-resistant (BLNAR) and TEM-1 {beta}-lactamase-producing amoxicillin/clavulanic acid-resistant (BLPACR) isolates of Haemophilus influenzae from patients with meningitis.

Methods: Between January 2000 and December 2004, we received 621 isolates of H. influenzae from 285 member institutions of the Nationwide Surveillance Study Group for Bacterial Meningitis. All isolates were analysed by PCR to identify resistance genes and tested for susceptibility to {beta}-lactams. The ftsI gene was sequenced in all BLNAR and BLPACR isolates.

Results: All but four isolates were of serotype b. The isolates could be divided into six classes, namely {beta}-lactamase-non-producing ampicillin-susceptible (25.0%), TEM-1 {beta}-lactamase-producing ampicillin-resistant (11.0%), {beta}-lactamase-non-producing low-level ampicillin-resistant with N526K or R517H substitution in the ftsI gene (30.4%), BLNAR with an S385T substitution together with either N526K or R517H substitution in ftsI (22.2%), BLPACR-I with either a N526K or R517H substitution in ftsI (9.5%) and BLPACR-II with an S385T substitution together with either a N526K or R517H substitution in ftsI (1.9%). The prevalence of BLNAR has increased rapidly, from 5.8% in 2000 to 34.5% in 2004. All BLNAR and BLPACR-II strains were classified into nine subgroups on the basis of substitution patterns in the ftsI gene. The MICs of cephalosporin antibiotics for H. influenzae transformants into which the ftsI genes from BLNAR strains of each of the nine subgroups were introduced increased to varying degrees depending on the mutations.

Conclusions: The results suggest that introduction of H. influenzae type b (Hib) vaccination into infants and children is necessary for the prevention of severe Hib infections in Japan.

Keywords: H. influenzae; BLNAR; PCR.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
Y. Hirakata, K. Ohmori, M. Mikuriya, T. Saika, K. Matsuzaki, M. Hasegawa, M. Hatta, N. Yamamoto, H. Kunishima, H. Yano, et al.
Antimicrobial Activities of Piperacillin-Tazobactam against Haemophilus influenzae Isolates, Including {beta}-Lactamase-Negative Ampicillin-Resistant and {beta}-Lactamase-Positive Amoxicillin- Clavulanate-Resistant Isolates, and Mutations in Their Quinolone Resistance-Determining Regions
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4225 - 4230.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Garcia-Cobos, J. Campos, F. Roman, C. Carrera, M. Perez-Vazquez, B. Aracil, and J. Oteo
Low {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Are Best Detected by Testing Amoxicillin Susceptibility by the Broth Microdilution Method
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2407 - 2414.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Garcia-Cobos, J. Campos, E. Lazaro, F. Roman, E. Cercenado, C. Garcia-Rey, M. Perez-Vazquez, J. Oteo, and F. de Abajo
Ampicillin-Resistant Non-{beta}-Lactamase-Producing Haemophilus influenzae in Spain: Recent Emergence of Clonal Isolates with Increased Resistance to Cefotaxime and Cefixime
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2564 - 2573.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
S. Tristram, M. R. Jacobs, and P. C. Appelbaum
Antimicrobial Resistance in Haemophilus influenzae
Clin. Microbiol. Rev., April 1, 2007; 20(2): 368 - 389.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.